

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM672696

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
CURIA GLOBAL, INC.	FORMERLY Albany Molecular Research, Inc.	09/01/2021	Corporation: DELAWARE
CURIA MASSACHUSETTS, INC.	FORMERLY AMRI Burlington, Inc.	09/01/2021	Corporation: MASSACHUSETTS
CURIA WISCONSIN, INC.	FORMERLY Cedarburg Pharmaceuticals, Inc.	09/01/2021	Corporation: DELAWARE
CURIA INDIANA, LLC	FORMERLY AMRI SSCI, LLC	09/01/2021	Limited Liability Company: DELAWARE
CURIA NEW MEXICO, LLC	FORMERLY Oso Biopharmaceuticals Manufacturing, LLC	09/01/2021	Limited Liability Company: DELAWARE
Curia IP Holdings, LLC		09/01/2021	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Wilmington Trust, National Association, as collateral agent		
Street Address:	1100 North Market Street		
City:	Wilmington		
State/Country:	DELAWARE		
Postal Code:	19890		
Entity Type:	National Banking Association: UNITED STATES		
PROPERTY NUMBERS Total: 9			
Property Type	Number	Word Mark	
Registration Number:	5192656	AMRI	
Registration Number:	5196964	AMRI	
Registration Number:	4911976	AMRI ALBANY MOLECULAR RESEARCH INC.	
Registration Number:	4911977	AMRI ALBANY MOLECULAR RESEARCH INC.	
Registration Number:	3360935	AMRI	
Registration Number:	4794054	SSCI	
Registration Number:	4928687	TRIADS	
Registration Number:	2306495		
Serial Number:	90721153	CURIA	

CH \$240.00 5192656

CORRESPONDENCE DATA**Fax Number:** 2028357586*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 202-835-7500**Email:** dcip@milbank.com**Correspondent Name:** Javier J. Ramos**Address Line 1:** 1850 K Street, NW, Suite 1100**Address Line 2:** Milbank, LLP**Address Line 4:** Washington, D.C. 20006

ATTORNEY DOCKET NUMBER:	39092.00045
--------------------------------	-------------

NAME OF SUBMITTER:	Javier J. Ramos
---------------------------	-----------------

SIGNATURE:	/Javier J. Ramos/
-------------------	-------------------

DATE SIGNED:	09/06/2021
---------------------	------------

Total Attachments: 28

source=Curia - Second Lien IP Security Agreement [Executed]#page1.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page2.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page3.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page4.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page5.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page6.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page7.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page8.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page9.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page10.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page11.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page12.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page13.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page14.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page15.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page16.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page17.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page18.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page19.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page20.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page21.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page22.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page23.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page24.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page25.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page26.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page27.tif
source=Curia - Second Lien IP Security Agreement [Executed]#page28.tif

SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT** (as amended, amended and restated, supplemented or otherwise modified from time to time, the “IP Security Agreement”) dated September 1, 2021, is among the Persons listed on the signature pages hereof (collectively, the “Grantors”) and Wilmington Trust, National Association, as collateral agent (the “Collateral Agent”) for the Secured Parties (as defined in the Credit Agreement referred to below).

WHEREAS, CURIA GLOBAL, INC., a Delaware corporation, and UIC PARENT CORPORATION, a Delaware corporation (“Holdings”), have entered into the Second Lien Credit Agreement dated as of September 1, 2021 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), with the lenders and financial institutions from time to time party thereto, WILMINGTON TRUST, NATIONAL ASSOCIATION, as Administrative Agent and Collateral Agent. Capitalized terms defined in the Credit Agreement or in the Security Agreement (as defined below) and not otherwise defined herein are used herein as defined in the Credit Agreement or the Security Agreement, as the case may be (and in the event of a conflict, the applicable definition shall be the one given to such term in the Security Agreement).

WHEREAS, as a condition precedent to the making of the Loans by the Lenders from time to time, each Grantor has executed and delivered that certain Second Lien Security Agreement dated September 1, 2021 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Grantors from time to time party thereto and the Collateral Agent.

WHEREAS, under the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Grantors, and have agreed thereunder to execute this IP Security Agreement for recording with the USPTO and/or the USCO, as applicable.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees as follows:

A. Grant of Security. Each Grantor hereby collaterally assigns and pledges to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, and each Grantor hereby grants to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, a security interest in and to all of such Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired by the undersigned (the “Collateral”):

a. all Patents, including the patents and patent applications set forth in Schedule A hereto (the “Patent Collateral”);

b. all Trademarks, including the trademark and service mark registrations and applications set forth in Schedule B hereto (provided that no security interest shall be granted in United States intent-to-use trademark applications prior to the filing of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto, to the extent that, and solely during the period, if any, in which, the grant of a security interest therein or the assignment thereof would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law), together with the goodwill symbolized thereby (the “Trademark Collateral”);

c. all Copyrights, whether registered or unregistered, including, without limitation, the copyright registrations and applications set forth in Schedule C hereto (the "Copyright Collateral");

d. all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

e. any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

f. any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing;

provided that notwithstanding anything to the contrary contained in the foregoing clauses (a) through (f), the security interest created hereby shall not extend to, and the term "Collateral" shall not include, any Excluded Property.

B. Security for Obligations. The grant of a security interest in, the Collateral by each Grantor under this IP Security Agreement secures the payment of all Secured Obligations of such Grantor now or hereafter existing under or in respect of the Loan Documents (as such Loan Documents may be amended, amended and restated, supplemented, replaced, refinanced or otherwise modified from time to time (including any increases of the principal amount outstanding thereunder)), whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise. Without limiting the generality of the foregoing, this IP Security Agreement secures, as to each Grantor, the payment of all amounts that constitute part of the Secured Obligations that would be owed by such Grantor to any Secured Party under the Loan Documents but for the fact that they are unenforceable or not allowable due to the existence of a bankruptcy, or reorganization or similar proceeding involving a Loan Party.

C. Recordation. Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks record this IP Security Agreement.

D. Execution in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Any signature to this IP Security Agreement may be delivered by facsimile, electronic mail (including pdf) or any electronic signature complying with the U.S. federal ESIGN Act of 2000 or the New York Electronic Signature and Records Act or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes to the fullest extent permitted by applicable law.

E. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. In the event of any

conflict between the terms of this IP Security Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern.

F. Governing Law; Jurisdiction; Etc.

1. THIS IP SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO THE CONFLICTS OF LAWS PRINCIPLES THEREOF, BUT INCLUDING SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW.

(b) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK CITY IN THE BOROUGH OF MANHATTAN AND OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK SITTING IN THE BOROUGH OF MANHATTAN, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS IP SECURITY AGREEMENT SHALL AFFECT ANY RIGHT THAT THE COLLATERAL AGENT OR ANY LENDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS IP SECURITY AGREEMENT OR THE RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT AGAINST ANY LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.

(c) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT IN ANY COURT REFERRED TO IN CLAUSE (b) OF THIS SECTION 6. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.


(d) EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.02 OF THE CREDIT AGREEMENT. NOTHING IN THIS IP SECURITY AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.

(e) EACH PARTY TO THIS IP SECURITY AGREEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND,


ACTION OR CAUSE OF ACTION ARISING UNDER THIS IP SECURITY AGREEMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS IP SECURITY AGREEMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS IP SECURITY AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF SECTION 10.17 OF THE CREDIT AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

IN WITNESS WHEREOF, each Grantor and the Collateral Agent have caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first written above.


CURIA GLOBAL, INC.

By: 
Name: Jason Knoblauch
Title: Treasurer


CURIA MASSACHUSETTS, INC.

By  _____
Name: Jason Knoblauch
Title: Treasurer


CURIA WISCONSIN, INC.

By: 
Name: Jason Knoblauch
Title: Treasurer

CURIA INDIANA, LLC


By: 
Name: Stacie Phillips
Title: Manager

CURIA NEW MEXICO, LLC

By: 
Name: Stacie Phillips
Title: Representative in the Management of the
Affairs of Curia New Mexico, LLC


CURIA IP HOLDINGS, LLC

By: Curia Global, Inc., as its sole member

By: 
Name: Jason Knoblauch
Title: Treasurer

**WILMINGTON TRUST, NATIONAL
ASSOCIATION**

as Collateral Agent

By: _____

Name: Andrew Lennon

Title: Assistant Vice President

SCHEDULE A

UNITED STATES PATENTS:

TITLE	APPLICATION NO	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
VINCA DERIVATIVES	11/697,415	4/6/2007	11/25/2014	8,895,543 ¹	Albany Molecular Research, Inc.
VINCA DERIVATIVES	11/003,560	12/3/2004	7/3/2007	7,238,704 ²	Albany Molecular Research, Inc.
VINCA DERIVATIVES	11/933,259	10/31/2007	6/29/2010	7,745,619 ³	Albany Molecular Research, Inc.
VINCA DERIVATIVES					Albany Molecular Research, Inc.
VINORELBINE DERIVATIVES					Albany Molecular Research, Inc.
VINORELBINE DERIVATIVES	12/331,691	12/10/2008	11/30/2010	7,842,802 ⁴	Albany Molecular Research, Inc.
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	11/487,884	7/17/2006	6/7/2011	7,956,050 ⁵	Albany Molecular Research, Inc.
ARYL- AND HETEROARYL-	12/598,882	5/8/2008	8/4/2015	9,096,546 ⁶	Albany Molecular Research, Inc.

¹ Albany Molecular Research, Inc. intends to abandon this patent
² Albany Molecular Research, Inc. intends to abandon this patent
³ Albany Molecular Research, Inc. intends to abandon this patent
⁴ Albany Molecular Research, Inc. intends to abandon this patent
⁵ Albany Molecular Research, Inc. intends to abandon this patent
⁶ Albany Molecular Research, Inc. intends to abandon this patent

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN					
ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN	12/598,912	5/8/2008	3/24/2015	8,987,252 ⁷	Albany Molecular Research, Inc.
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	12/917,066	11/1/2010	7/29/2014	8,791,101 ⁸	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL	13/108,651	5/16/2011	1/31/2012	8,106,244	Albany Molecular Research, Inc.

⁷ Albany Molecular Research, Inc. intends to abandon this patent
⁸ Albany Molecular Research, Inc. intends to abandon this patent

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF	12/473,940	5/28/2009	2/28/2012	8,124,600	Albany Molecular Research, Inc.
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF	13/372,967	2/14/2012	8/6/2013	8,501,729	Albany Molecular Research, Inc.
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF	13/941,304	7/12/2013	4/29/2014	8,710,047	Albany Molecular Research, Inc.
ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF	12/884,650	9/17/2010	6/17/2014	8,754,054 ⁹	Albany Molecular Research, Inc.
ANTI-INFECTIVE COMPOUND					Albany Molecular Research, Inc.
TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF	13/331,814	12/20/2011	3/31/2015	8,993,765 ¹⁰	Albany Molecular Research, Inc.
NITROGEN SUBSTITUTED BIARYL PURINE DERIVATIVES AS POTENT ANTIPROLIFERATIVE AGENTS	10/680,832	10/7/2003	9/27/2005	6,949,559	Albany Molecular Research, Inc.
METHOD FOR ENZYMATIC					Albany Molecular Research, Inc.

⁹ Albany Molecular Research, Inc. intends to abandon this patent

¹⁰ Albany Molecular Research, Inc. intends to abandon this patent

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
GLYCOSYLATION OF INSULIN					
CYCLOSPORINS	10/802,013	3/16/2004	5/26/2009	7,538,084	Albany Molecular Research, Inc.
AZA-PYRAZOLOACRIDINES WITH POTENTIAL ANTITUMOR ACTIVITY					Albany Molecular Research, Inc.
ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUOLINES AND USE THEREOF	10/426,097	4/29/2003	11/3/2009	7,612,090 ¹¹	Albany Molecular Research, Inc.
SYNTHESIS OF CF-101					Albany Molecular Research, Inc.
COMPOUNDS WHICH INHIBIT SEROTONIN, DOPAMINE, AND NOREPINEPHRINE TRANSPORT					
NOVEL R-PHENYL SUBSTITUTED TETRAHYDROISOQUOLINES AND USE THEREOF					
ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUOLINES AND USE THEREOF					
SYSTEM AND METHOD OF DEVELOPING MOLECULAR MINI-FINGERPRINTS FOR IDENTIFYING					Albany Molecular Research, Inc.

¹¹ Albany Molecular Research, Inc. intends to abandon this patent

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
COMPOUNDS HAVING SIMILAR ACTIVITY AND VIRTUAL SCREENING PROCESS FOR PREPARING MENTHADIENOL					
NOVEL PROCESSES FOR STEREOSELECTIVE SYNTHESIS OF TRANS ISAtx247 [cyclosporin]	11/572,833	7/26/2005	9/21/2010	7,799,756	Albany Molecular Research, Inc.
NOVEL CYCLOSPORIN ANALOGUES AND THEIR PHARMACEUTICAL USES	11/232,292	9/21/2005	3/31/2009	7,511,013	Albany Molecular Research, Inc.
NOVEL CYCLOSPORIN ALKYNES AND THEIR UTILITY AS PHARMACEUTICAL AGENTS	12/046,854	3/12/2008	12/15/2009	7,632,807	Albany Molecular Research, Inc.
2,5-METHANO- and 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN	13/211,678	8/17/2011	6/2/2015	9,045,468 ¹²	Albany Molecular Research, Inc.
SPIROINDANES AS MONOAMINE REUPTAKE INHIBITORS					Albany Molecular Research, Inc.
Synthesis of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-					

¹² Albany Molecular Research, Inc. intends to abandon this patent

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
tetrahydroisquinolin-7-ylpyridizin-3-amine					
SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA					Albany Molecular Research, Inc.
BENZOFURO[3,2-C]PYRIDINE AND AZEPINE ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA	13/352,864	1/18/2012	6/30/2015	9,067,949 ¹³	Albany Molecular Research, Inc.
AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF	12/828,890	7/1/2010	12/31/2013	8,618,299 ¹⁴	Albany Molecular Research, Inc.
AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF	12/828,955	7/1/2010	7/7/2015	9,073,925 ¹⁵	Albany Molecular Research, Inc.

¹³ Albany Molecular Research, Inc. intends to abandon this patent

¹⁴ Albany Molecular Research, Inc. intends to abandon this patent

¹⁵ Albany Molecular Research, Inc. intends to abandon this patent

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
NOVEL AZACARBOLINES					Albany Molecular Research, Inc.
NOVEL AZACARBOLINES					Albany Molecular Research, Inc.
NOVEL CARBAZOLES					Albany Molecular Research, Inc.
ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF	12/777,728	5/11/2010	5/19/2015	9,034,899	Albany Molecular Research, Inc.
7-([1,2,4]TRIAZOLO[1,5-a]PYRIDINYL-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF	12/777,776	5/11/2010	8/12/2014	8,802,696	Albany Molecular Research, Inc.
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF	12/777,840	5/11/2010	8/26/2014	8,815,894	Albany Molecular Research, Inc.
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF	14/466,009	8/22/2014	11/3/2015	9,173,879 ¹⁶	Albany Molecular Research, Inc.

¹⁶ Albany Molecular Research, Inc. intends to abandon this patent

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF	13/151,992	6/2/2011	6/2/2015	9,045,445	Albany Molecular Research, Inc.
ARYL- AND HETEREROARYL-SUBSTITUTED TETRAHYDROISOQUOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN					
ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUOLINES AND USE THEREOF	14/593,750	1/9/2015	3/28/2017	9,604,960	Albany Molecular Research, Inc.
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN					
PREPARATION OF DEXAMPHETAMINE					Albany Molecular Research, Inc.
VINCA DERIVATIVES					Albany Molecular Research, Inc.
PROCESSES FOR PREPARING	14/774,522	9/10/2015			Albany Molecular Research, Inc.

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
TETRAHYDROISOQUINOLINES					
PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION	08/994,357	12-19-1997	11-30-1999	5,994,549	Albany Molecular Research, Inc.
PROCESS FOR ASEPTIC VACUUM FILLING AND STOPPERING OF LOW VISCOSITY LIQUIDS IN SYRINGES	11/657,814	1/25/2007	2/12/2008	7,328,549 ¹⁷	AMRI BURLINGTON, INC.
SYRINGE LYOPHILIZATION METHODS AND APPARATUS					AMRI BURLINGTON, INC.
EXEMESTANE AND ITS INTERMEDIATES AND METHODS OF MAKING THE SAME	10/586,237	6/6/2008	5/22/2012	8,183,401	CEDARBURG PHARMACEUTICALS INC.
EXEMESTANE AND ITS INTERMEDIATES AND METHODS OF MAKING THE SAME	13/451,034	4/19/2012	9/24/2013	8,541,609	CEDARBURG PHARMACEUTICALS INC.
PREPARATION OF AMIDES OF RETINOIC ACID VIA MIXED ANHYDRIDE AND MIXED CARBONATE INTERMEDIATES	11/715,571	3/8/2007	1/22/2008	7,321,064 ¹⁸	CEDARBURG PHARMACEUTICALS INC.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	12/356,282	1/20/2009	1/4/2011	7,863,452	Albany Molecular Research, Inc.

¹⁷ Albany Molecular Research, Inc. intends to abandon this patent
¹⁸ Albany Molecular Research, Inc. intends to abandon this patent

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	12/956,601	11/30/2010	11/29/2011	8,067,605	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	10/212,854	8/5/2002	12/13/2005	6,974,872	Albany Molecular Research, Inc.
PROCESS FOR THE PRODUCTION OF PIPERIDINE DERIVATIVES WITH MICROORGANISMS	09/754,786	1/4/2001	9/2/2003	6,613,907	Albany Molecular Research, Inc.
PROCESS FOR THE PRODUCTION OF PIPERIDINE DERIVATIVES WITH MICROORGANISMS	10/638,841	8/11/2003	6/19/2007	7,232,908	Albany Molecular Research, Inc.
PROCESS FOR THE PRODUCTION OF PIPERIDINE DERIVATIVES WITH MICROORGANISMS	11/624,096	1/17/2007	4/6/2010	7,691,615	Albany Molecular Research, Inc.
METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE	15/431,572	2/13/2017			Albany Molecular Research, Inc.
METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE	15/431,624	2/13/2017			Albany Molecular Research, Inc.
OPIOID PRODRUGS OF HYDROCODONE AND HYDROMORPHONE					
LOW-BACKGROUND SCATTERING X-RAY DIFFRACTOMETER DEVICES, SYSTEMS AND METHODS	13/302,474	11/22/2011	5/27/2014	8,737,564	AMRI SSCI, LLC

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
SYSTEM AND METHOD FOR MATCHING DIFFRACTION PATTERNS	10/635,113	8/6/2003	5/13/2008	7,372,941	AMRI SSCI, LLC
SYSTEM AND METHOD FOR MATCHING DIFFRACTION PATTERNS	11/935,965	11/6/2007	5/11/2010	7,715,527	AMRI SSCI, LLC
METHODS FOR INDEXING SOLID FORMS OF COMPOUNDS	12/871,421	8/30/2010	11/5/2013	8,576,985	AMRI SSCI, LLC
POLYMORPHS OF COCRYSTALS OF p-CUMARIC ACID: NICOTINAMIDE	14/607,186	1/28/2015	4/19/2016	9,314,459	AMRI SSCI, LLC
POLYMORPHS OF COCRYSTALS OF p-CUMARIC ACID: NICOTINAMIDE	15/072,530	3/17/2016	3/17/2016	10,004,726	AMRI SSCI, LLC
NOVEL COCRYSTALLIZATION	10/763,987	1/21/2004	11/18/2008	7,452,555	AMRI SSCI, LLC
COCRYSTALLIZATION	12/234,093	9/19/2008	7/3/2012	8,212,079	AMRI SSCI, LLC
PREPARATION OF MANNITOL MODIFICATION III	12/601,270	5/21/2008	3/5/2013	8,389,778	AMRI SSCI, LLC
SAMPLE HOLDER AND SAMPLE PREPARATION DEVICE	12/133,675	6/5/2008	9/13/2011	8,018,588	AMRI SSCI, LLC
METHODS OF MAKING COCRYSTALS	13/657,259	10/22/2012	9/1/2015	9,120,766	AMRI SSCI, LLC
SCREENING FOR SOLID FORMS BY ULTRASOUND CRYSTALLIZATION AND	12/888,052	9/22/2010	12/30/2014	8,920,559 ¹⁹	AMRI SSCI, LLC

¹⁹ Albany Molecular Research, Inc. intends to abandon this patent





TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
COCRYSTALLIZATION USING ULTRASOUND					
COCRYSTALS OF P-COUMARIC ACID	14/017,879	9/4/2013	10/16/18	10,098,859	AMRI SSCI, LLC
COCRYSTALS OF PROGESTERONE	14/017,397	9/4/2013	12/6/2016	9,512,166	AMRI SSCI, LLC
COCRYSTALS OF PROGESTERONE	15/333,691	10/25/2016	5/29/2018	9,982,007	AMRI SSCI, LLC
NOVEL SYNTHESIS OF ERIBULIN MESYLATE					AMRI SSCI, LLC
AMORPHOUS DISPERSIONS OF EPIGALLOCATECHIN GALLATE	62/535,075	7/20/2017			AMRI SSCI, LLC
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	08/576,068	12/21/1995	11/28/2000	6,153,754	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	12/483,002	06-11-2009	09-20-2011	8,022,220	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	12/951,644	11-22-2010	11-29-2011	8,067,604	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF CAREBASTINE	12/356,277	01-20-2009	12-28-2010	7,858,798	Albany Molecular Research, Inc.
Synthesis of 2-AMINO BENZOXAZOLE compounds	12/604,491	10-23-2009	05-15-2012	8,178,666	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	08/575,344	12/21/1995	3/13/2001	6,201,124	Albany Molecular Research, Inc.

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	09/634,983	8/9/2000	9/3/2002	6,444,824	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	09/634,775	8/9/2000	9/10/2002	6,448,406 - expired	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	09/634,169	8/9/2000	9/17/2002	6,452,011	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	09/637,127	8/9/2000	10/1/2002	6,458,958	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	11/521,820	9/15/2006	3/16/2010	7,678,915	Albany Molecular Research, Inc.
AZA-ACRIDINES WITH POTENTIAL ANTITUMOR ACTIVITY					Albany Molecular Research, Inc.
SUBSTANTIALLY PURE IBOGAMINE CONGENER ENANTIOMERS					Albany Molecular Research, Inc.
METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF	15/572,372	5/5/2016	3/24/2020	10,597,401	Albany Molecular Research, Inc.

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
POLYMORPHS OF COCRYSTALS OF EPIGALLOCATECHIN GALLATE AND CAFFEINE	15/756,213	9/1/2016	6/22/2020	10,813,938	AMRI SSCI, LLC

SCHEDULE B

UNITED STATES TRADEMARKS:

TRADEMARK	COUNTRY	APP. DATE	APP. NO.	REG. NO.	REG. DATE.	OWNER
	US	3/23/2016	86950416	5192656	4/25/2017	ALBANY MOLECULAR RESEARCH, INC.
	US	3/23/2016	86950456	5196964	5/2/2017	ALBANY MOLECULAR RESEARCH, INC.
	US	10/02/2014	86/413,276	4911976	3/8/2016	ALBANY MOLECULAR RESEARCH, INC.
	US	10/02/2014	86/413,314	4911977	3/8/2016	ALBANY MOLECULAR RESEARCH, INC.
AMRI	US	7/13/2006	78/928,960	3,360,935	12/25/2007	ALBANY MOLECULAR RESEARCH, INC.

TRADEMARK	COUNTRY	APP. DATE	APP. NO.	REG. NO.	REG. DATE.	OWNER
SSCI & Design 	US	12/22/2014	86/487,754	4,794,054	8/18/2015	AMRI SSCI, LLC
TRIADS	US	12/22/2014	86/487,769	4928687	3/29/2016	AMRI SSCI, LLC
design	US	12/9/1997	75402494	2306495 ²⁰	1/4/2000	CEDARBURG PHARMACEUTICALS INC.
CEDARBURG LABORATORIES ²¹	US Wisconsin				7/5/2000	Cedarburg Pharmaceuticals, LLC
CURIA	US	5/19/2021	90721153			Curia IP Holdings, LLC

²⁰ Albany Molecular Research, Inc. intends to abandon this trademark

²¹ Albany Molecular Research, Inc. intends to abandon this trademark

SCHEDULE C

UNITED STATES COPYRIGHTS:

NAME (NALL) <	FULL TITLE	COPYRIGHT NUMBER	DATE
Albany Molecular Research, Inc.	AMRI's fine chemicals catalog.	VA0001209570	2003
AMRI	Publications Patents Presentations. [Published: 2008-10-17. Issue: vol. 2, July 2001 - October 2007]	TX0007039445	2008